Related Experiment Video
Updated: Apr 15, 2026

Monitoring Hippo Signaling Pathway Activity Using a Luciferase-based Large Tumor Suppressor LATS Biosensor
Published on: September 13, 2018
Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells
Upal Basu-Roy1, N Sumru Bayin2, Kirk Rattanakorn1
1Department of Microbiology, New York University School of Medicine, New York, New York 10016, USA.
Abstract:
The repressive Hippo pathway has a profound tumour suppressive role in cancer by restraining the growth-promoting function of the transcriptional coactivator, YAP. We previously showed that the stem cell transcription factor Sox2 maintains cancer stem cells (CSCs) in osteosarcomas. We now report that in these tumours, Sox2 antagonizes the Hippo pathway by direct repression of two Hippo activators, Nf2 (Merlin) and WWC1 (Kibra), leading to exaggerated YAP function. Repression of Nf2, WWC1 and high YAP expression marks the CSC fraction of the tumor population, while the more differentiated fraction has high Nf2, high WWC1 and reduced YAP expression. YAP depletion sharply reduces CSCs and tumorigenicity of osteosarcomas. Thus, Sox2 interferes with the tumour-suppressive Hippo pathway to maintain CSCs in osteosarcomas. This Sox2-Hippo axis is conserved in other Sox2-dependent cancers such as glioblastomas. Disruption of YAP transcriptional activity could be a therapeutic strategy for Sox2-dependent tumours.
Insights
Sox2 maintains osteosarcoma cancer stem cells by repressing the Hippo pathway, increasing YAP activity. Targeting YAP offers a potential therapy for Sox2-driven cancers like osteosarcomas and glioblastomas.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Stem Cell Biology
Background:
- The Hippo pathway is a tumor suppressor that inhibits YAP, a growth-promoting coactivator.
- Sox2 maintains cancer stem cells (CSCs) in osteosarcomas.
Purpose of the Study:
- To investigate how Sox2 maintains CSCs in osteosarcomas.
- To elucidate the interaction between Sox2, the Hippo pathway, and YAP in osteosarcoma.
Main Methods:
- Analysis of Sox2, Hippo pathway components (Nf2, WWC1), and YAP expression in osteosarcoma CSCs and differentiated cells.
- Assessment of YAP function and tumorigenicity upon YAP depletion in osteosarcomas.
Main Results:
- Sox2 directly represses Hippo pathway activators Nf2 (Merlin) and WWC1 (Kibra) in osteosarcoma CSCs.
- This repression leads to enhanced YAP activity, which is characteristic of the CSC fraction.
- YAP depletion significantly reduces CSCs and osteosarcoma tumorigenicity.
- The Sox2-Hippo-YAP axis is conserved in Sox2-dependent cancers like glioblastomas.
Conclusions:
- Sox2 promotes osteosarcoma CSC maintenance by antagonizing the tumor-suppressive Hippo pathway, thereby increasing YAP function.
- Targeting YAP transcriptional activity presents a potential therapeutic strategy for Sox2-dependent tumors.
Related Concept Videos
Hedgehog Signaling Pathway
Hedgehog Signaling Pathway
Pleiotropy
Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer Stem Cells and Tumor Maintenance
Role Of Notch Signalling In Intestinal Stem Cell Renewal
Direct cell-to-cell contact is needed for the activation of Notch signaling. The signal is initiated when a notch ligand binds to a receptor on an adjacent cell, also...

